Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: SPDU.OB), announced ... present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Time at The Palace Hotel in San Francisco, ... and an update on its clinical,development programs, including ...
... Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today ... outstanding shares,of Apollo Light Systems, Inc., a 20-year-old, ... therapy systems for melatonin suppression and,circadian rhythm sleep ... is located in American Fork, Utah and has ...
... 2 Monitorforhire.com, the,fastest source for hiring ... faster. The company has added a mobile ... immediately to work requests via,PDA or cell ... Freedman, president of monitorforhire.com says that adding ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 2Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 3Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... lived on the land now called California, and many ... of plants they used for food, fuel, tools, and ... desired habitat and natural resources. , Frank Lake, an ... will lead a field trip to the ... of America,s 99th Annual Meeting, in Sacramento, Cal. this ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... as we grow older, our bones become more brittle and ... of mass is a major reason for older bones fracturing ... on slowing down this loss. However, new research from scientists ... Laboratory (Berkeley Lab) shows that at microscopic dimensions, the age-related ...
... Winston-Salem, N.C. -- New research from Wake Forest ... electronics by developing, for the first time, an ... electrical properties, and inexpensive to produce. ... of physics at Wake Forest, her graduate students ...
... 2011 Neurotechnology , a provider ... the availability of SentiSight 3.0 , a Software ... version adds shape-based recognition and offers enhanced local-feature-based recognition ... also includes enhanced tracking of fast moving objects and ...
Cached Biology News:The brittleness of aging bones -- more than a loss of bone mass 2The brittleness of aging bones -- more than a loss of bone mass 3Flexible electronics hold promise for consumer applications 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 3SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 4
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The ubiquitin-proteasome pathway is the major ... eukaryotic cells, where it catalyzes the ... and the rapid elimination of proteins ... 1998; Hochstrasser 1996). The critical protease ...
... technology enables sensitive, fast and specific detection ... Short hybridisation time ( ... chromosome spreads Multiplex capability Available ... Probes available with different labels. ...
... * Source rat ... T25 plated cells $550.00, * ... 120 population doublings, * This ... complete ,growth medium M55007-08 and ...
Biology Products: